secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001171843-23-006206
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus announces multiple abstracts accepted for AASLD 2023, including late-breaking imdusiran data
--------------------------------------------------------------------------------

- Late-breaking poster on imdusiran (AB-729) followed by VTP-300 or placebo in chronic hepatitis B subjects.
- Poster #1459-C shows baseline HBV SNPs do not impact HBsAg reductions from imdusiran.
- Oral presentation on 48-week vebicorvir + imdusiran + NrtI combination in eAg-negative CHB (Nov 12).
- Preclinical data on oral small-molecule liver-tropic PD-L1 inhibitor for HCC (Nov 13).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006206/0001171843-23-006206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323006206/f8k_101123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer